Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

Persistence of IDH1 or IDH2 mutations in remission bone marrow specimens of patients with acute myeloid leukemia has been observed, but the clinical impact of these mutations is not well known. In this study, we evaluated 80 acute myeloid leukemia patients with known IDH1 R132 or IDH2 R140/R172 muta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Ok, Chi Young, Loghavi, Sanam, Sui, Dawen, Wei, Peng, Kanagal-Shamanna, Rashmi, Yin, C. Cameron, Zuo, Zhuang, Routbort, Mark J., Tang, Guilin, Tang, Zhenya, Jorgensen, Jeffrey L., Luthra, Rajyalakshmi, Ravandi, Farhad, Kantarjian, Hagop M., DiNardo, Courtney D., Medeiros, L. Jeffrey, Wang, Sa A., Patel, Keyur P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355476/
https://ncbi.nlm.nih.gov/pubmed/30171025
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.191148
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller